

# A Recommendation From Their HCP Is the Strongest Predictor of Adults Getting Vaccinated<sup>1</sup>

## The CDC recommends<sup>2</sup>:



Adults 50-74 years of age who are at increased risk of severe RSV disease\* receive a single dose of RSV vaccine



Adults 75 years of age and older receive a single dose of RSV vaccine

## Additional information from the CDC

Eligible adults are currently recommended to receive a single dose of RSV vaccine; adults who have already received RSV vaccination should not receive another dose. Eligible adults may be vaccinated at any time of year, but vaccination will have the most benefit if administered in late summer or early fall, just before the RSV season.<sup>2</sup>

\*For a full list of risk factors, please refer to the CDC website.

Not an actual patient.

Jamar, aged 68 | COPD



## Consider these conversation points as you discuss vaccination with your appropriate patients:



### STRESS THE URGENCY

Discuss with your patients why their age and certain conditions may put them at increased risk for severe RSV infections.<sup>3</sup>



### DISCUSS AREXVY

Provide information about AREXVY and why it may be an appropriate option for older patients and those with certain underlying conditions. Help them assess the risks and benefits of vaccination.<sup>4</sup>



### ENSURE VACCINATION

For patients who are identified to receive AREXVY, give a tearpad reminder, send an electronic prescription to their pharmacy, or help them schedule with EasyVax™ (Powered by GSK) online today. Follow up to confirm they were able to receive AREXVY.

Please turn over for more information on additional resources.

CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease; HCP=healthcare provider; RSV=respiratory syncytial virus.

## Indication

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.

## Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY

Please see additional Important Safety Information on the reverse and accompanying full Prescribing Information, also available at [AREXVYhcp.com](http://AREXVYhcp.com).

**AREXVY**  
(RESPIRATORY SYNCYTIAL VIRUS  
VACCINE, ADJUVANTED)



# Help Facilitate the Vaccination Process for Your Patients

## A suite of resources to help guide your patients

- EasyVax™ vaccine scheduler tool
- Electronic prescription sent from EHR to your patients' pharmacy
- Paper scripts for your patients
- Patient handouts with vaccination information\*
- "What to Expect" resource that outlines the clinical information for AREXVY\*



**EasyVax™**  
Powered by GSK



Not an actual patient.

\*Contact your GSK sales representative for this resource.  
EHR=electronic health record.

## Important Safety Information (cont.)

- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- In adults 60 years of age and older, the most commonly reported adverse reactions ( $\geq 10\%$ ) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- In adults 50 through 59 years of age, the most commonly reported adverse reactions ( $\geq 10\%$ ) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients

**Please see additional Important Safety Information on the reverse and accompanying full Prescribing Information, also available at AREXVYhcp.com.**

**You and your staff can find more on RSV and AREXVY, as well as RSV patient stories, at AREXVYhcp.com.**

**References:** 1. Vaccine information for adults. Strategies for increasing adult vaccination rates. Centers for Disease Control and Prevention. Accessed June 25, 2025. <https://www.cdc.gov/vaccines-adults/hcp/vaccination-guidelines/index.html> 2. Respiratory syncytial virus infection (RSV). RSV vaccine guidance for adults. Centers for Disease Control and Prevention. Accessed July 10, 2025. <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html> 3. Respiratory syncytial virus infection (RSV). RSV in adults. Centers for Disease Control and Prevention. Accessed July 11, 2025. <https://www.cdc.gov/rsv/adults/> 4. Prescribing Information for AREXVY.

Trademarks are owned by or licensed to the GSK group of companies.

©2025 GSK or licensor.  
PMUS-RSALBND250023 August 2025  
Produced in USA. 0002-0039-76

**AREXVY**  
(RESPIRATORY SYNCYTIAL VIRUS  
VACCINE, ADJUVANTED)

